No Data
No Data
KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Deliver On Growth Plans?
H.C. Wainwright Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $20
KalVista Pharmaceuticals Presents New Data Showing Effectiveness Of Sebetralstat In Reducing Anxiety During Attacks; Supports Need For Oral On-Demand Option To Treat Attacks Earlier And More Often At The 2024 HAEi Global Angioedema Forum
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Kalvista Pharmaceuticals Inc - Sebetralstat Phase 3 Trial Meets Primary Endpoint
No Data
No Data